MRK drops omarigliptin (weekly Januvia) program for “business reasons”: http://www.mercknewsroom.com/news/company-statements/merck-provides-update-filing-plans-omarigliptin-investigational-dpp-4-inhibi Omarigliptin was found non-inferior to Januvia in a head-to-head comparison (#msg-117018184); however, the DPP-4 space has become unduly crowded.